You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Graspable Math Activities
SBC: GRASPABLE INC Topic: 91990019R0012Graspable Math Activities is web application that middle and high school students use on laptops and tablets to practice algebra and receive instantaneous feedback. Activities are based on an algebra notation technology that can promote procedural fluency while allowing students to focus on strategy and the connection between concepts and procedures. The team will produce a website that will inclu ...
SBIR Phase II 2019 Department of EducationInstitute of Education Sciences -
Object Oriented Data Analysis for Untargeted Metabolomics
SBC: WILLIAM D SHANNON CONSULTING LLC Topic: 400PROJECT SUMMARY ABSTRACT In this Phase I SBIR applicationwe propose to develop and optimize functional Object Oriented Data AnalysisfOODAmethods and create a cloud based SaaS platform to analyze untargeted metabolomics dataUntargeted metabolomics quantifies the amount of known and unknown metabolites in samples with the purpose of finding known and unknown metabolites that correlate with subgroups ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation
SBC: NEWVENTUREIQ LLC Topic: NIAIDABSTRACT Human leukocyte antigenHLAtyping is an essential laboratory test to evaluate the donor recipient compatibility before life saving transplantationsInaloneHLA typing of donors and recipients guided overorgan and stem cell transplantations in the United StatesExisting high resolution HLA typing methods require a turnaround time of days to weeksThere has been an unmet clinical need for a rapi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biologically Targeted Vaccine for Chikungunya
SBC: PRECISION VIROLOGICS INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Magnetomotive Embolization for Hepatocellular Carcinoma
SBC: UNANDUP, LLC Topic: 102Cancer is thend leading cause of death in the United StatesUSand accounts forof everydeathsMore thanAmericans will die of cancer inwith annual US cancer care expenditures reaching $B byand more thanM cancer related deaths occur annuallyWhile chemotherapy is effectiveseveral cancer subtypesincluding liver cancerare associated with a very lowyear survival rate of less thanIn additiononly a small pro ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Soluble, solution-stable phospho-glucagon for hypoglycemic rescue
SBC: MONON BIOVENTURES LLC Topic: 200PROJECT SUMMARY Hypoglycemiaa decrease in blood sugar levelsis a common occurrence for themillion Americans with diabetesIn severe hypoglycemiathe individual is at risk for diabetic coma and even deathAlthough these events can be managed using a glucagon emergency kitcurrent kits require a multi step procedure in which lyophilized glucagon is reconstituted and administered as an injectionEmergency ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer
SBC: Medical Guidance Systems LLC Topic: 102The proposed developmental activity will result in a humanized monoclonal antibody, Tiptuhumab, which acts as a radiomodulator/immunotherapeutic. This antibody targets the cancer neoantigen, Tax Interacting Protein-1 (TIP-1), and is cytotoxic to non-small-cell lung cancer cells, NSCLC. For patients with NSCLC, the 5-year overall survival rate is 14.9% with a median survival time of 4 months. The c ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Probiotic Platform to Treat Necrotizing Enterocolitis
SBC: Scioto Biosciences Inc. Topic: 300PROJECT SUMMARY Necrotizing enterocolitis (NEC) is a devastating disease affecting premature infants. Approximately 10% of infants born under 1500 g will develop the disease, and mortality for affected infants is 20-30%. Despite decades of research, the morbidity and mortality of the disease remain generally unchanged. Current treatment and preventive approaches for NEC remain suboptimal, with no ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel immunomodulatory pyridone for the treatment of acute heart damage
SBC: I-Cordis, LLC Topic: NHLBIProject summary abstract In the USpeople per year develop heart failure from acute heart damagemostly from heart attacksApproximatelyof them die withinyears of the heart failure diagnosisCurrentlythere are no therapies to prevent the development of heart failure after acute heart damageA growing body of evidence points at Pirfenidonea pyridone currently approved for the treatment of a rare disease ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health